• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ZimVie Pioneers the Future of Molar Restoration with New Immediate Molar Dental Implant System

    4/21/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email

    PALM BEACH GARDENS, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its Immediate Molar Implant System in the United States. ZimVie is expanding its already clinically proven TSX® and T3 PRO® Implant systems with an immediate molar solution, simplifying challenging clinical scenarios for providers and shortening treatment times for patients requiring molar implants.

    Immediately replacing extracted molars with an implant can be difficult due to the complex multi-rooted anatomy and size of the tooth socket. ZimVie's Immediate Molar Implant System includes specially engineered instrumentation that streamlines site preparation in molar extraction, making it a more controlled and predictable procedure. The system also offers optimized wide-diameter implants that better fit the implant site for unmatched primary stability while potentially reducing the risk of peri-implantitis by up to 20% through its proprietary DAE coronal surface technology. Restorative compatibility with ZimVie's existing implant system minimizes switching costs.

    Conventional treatment protocols involve molar extraction, followed by months of healing before an implant can be placed. The ZimVie Immediate Molar Implant System allows the implant to be restored in half the time compared to traditional treatment, in a simplified, predictable manner.

    "The launch of our Immediate Molar Dental Implant System marks a significant milestone in our commitment to advancing dental technology," said ZimVie CEO Vafa Jamali. "We have expanded the offering of our implant systems to address the unique challenges of molar tooth restoration and provide patients shorter and more cost-effective treatment while delivering a more predictable, lasting outcome."

    For more information on ZimVie's dental implants, suite of connected solutions, and continuing education, please visit www.zimvie.com.

    A Media Snippet accompanying this announcement is available by clicking on this link.

    About TSX Implants

    Launched in 2022, TSX Implants are designed for immediate extraction and standard loading protocols as well as placement predictability and primary stability in soft and dense bone. The Implant incorporates features with more than two decades of real-world, clinical data to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability,* including the Contemporary Hybrid Surface combination with coronal DAE. Integrated with ZimVie's end-to-end digital workflows and engineered with surgical and restorative versatility, the TSX Implant furthers ZimVie's commitment to simplify procedures and optimize practice protocols.

    About T3 PRO Implants

    Launched in 2022, the T3 PRO Implant's advanced design delivers high primary stability and allows for immediate function. T3 PRO has a hybrid surface featuring the proprietary Osseotite surface on the implant collar, as well as a rougher grit-blasted implant body. Not only have multiple long-term, independent clinical studies on the proprietary Osseotite surface demonstrated safety and performance,* they have also demonstrated the effect of this surface in preserving crestal bone. This Contemporary Hybrid Surface of T3 PRO along with the optional integrated platform switching design has also been shown to provide early and long-term peri-implant bone support.

    * References on file at ZimVie.

    About ZimVie

    ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.zimvie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie's filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.

    Media Contact Information:

    ZimVie

    Grace Flowers • [email protected]

    (561) 319-6130

    Investor Contact Information:

    Gilmartin Group LLC

    Webb Campbell • [email protected]

    A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99f92dfd-d794-4c29-96e4-209f3a10cd03



    Primary Logo

    Get the next $ZIMV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    3/18/2022Neutral
    Guggenheim
    More analyst ratings

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Jamali Vafa converted options into 21,331 shares and covered exercise/tax liability with 9,333 shares, increasing direct ownership by 3% to 360,257 units (SEC Form 4)

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/3/25 4:03:34 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Kuntz Richard

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/2/25 5:22:27 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director King David P

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/2/25 4:47:15 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    SEC Filings

    See more
    • SEC Form 10-Q filed by ZimVie Inc.

      10-Q - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:15:20 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:10:42 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by ZimVie Inc.

      DEFA14A - ZimVie Inc. (0001876588) (Filer)

      3/25/25 8:05:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results

      FY2024 Third Party Net Sales from Continuing Operations of $449.7 millionFY2024 Net Loss from Continuing Operations of $(33.8) million; Net Loss margin of (7.5%) FY2024 Adjusted EBITDA[1] from Continuing Operations of $60.0 million; Adjusted EBITDA[1] margin of 13.3%FY2024 GAAP diluted EPS from Continuing Operations of $(1.23) and adjusted diluted EPS[1] of $0.62 PALM BEACH GARDENS, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2

      2/26/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie to Report First Quarter 2025 Financial Results on May 8, 2025

      PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactu

      4/24/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Pioneers the Future of Molar Restoration with New Immediate Molar Dental Implant System

      PALM BEACH GARDENS, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its Immediate Molar Implant System in the United States. ZimVie is expanding its already clinically proven TSX® and T3 PRO® Implant systems with an immediate molar solution, simplifying challenging clinical scenarios for providers and shortening treatment times for patients requiring molar implants. Immediately replacing extracted molars with an implant can be difficult due to the complex multi-rooted anatomy and size of the tooth socket. ZimVie's Immediate Molar Implant System includes specially engineered instru

      4/21/25 8:00:00 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ZimVie Inc.

      SC 13G - ZimVie Inc. (0001876588) (Subject)

      11/14/24 4:11:11 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      11/14/24 10:58:06 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

      SC 13G/A - ZimVie Inc. (0001876588) (Subject)

      10/4/24 1:02:25 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on ZimVie with a new price target

      B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

      4/10/25 12:44:28 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie downgraded by Needham

      Needham downgraded ZimVie from Buy to Hold

      3/13/25 7:58:34 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie upgraded by Needham with a new price target

      Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00

      5/16/24 7:42:36 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    See more
    • ZimVie Announces Upcoming Changes to Company's Board of Directors

      PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

      3/13/25 4:15:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care